News GlobeNewswire Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder ...

EG 427 Thu, Feb 20, 2025, 2:00 AM6 min read EG 427 ...

Paris, France, February 27, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology based on its unique HERMES ...

The financing will also support expansion of EG 427's pipeline with several therapeutic vectors based on its unique HERpes Modular Expression System (HERMES) technology. In these targeted diseases, ...

Paris, France, February 27, 2025 - EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology based on its unique HERMES vector ...